Peter Akerblad Ph.D leads a team in Bioscience CVMD bases in Mölndal Sweden that mainly focuses on cardiac regeneration in vitro biology. The team is also involved in Brilinta life cycle management and supporting late stage projects like Roxadustat. Peter is the AstraZeneca lead in the University of Virginia Alliance.